IDO inhibitors

1. A compound of Formula (I)

wherein:

W is CR 4 ,

V is CR 5 , and

Y is CR 6 ;

is optionally substituted aryl or optionally substituted 5- to 7-membered monocyclic heteroaryl;

R 1 is COOH, optionally substituted heterocyclyl, —NHSO 2 R 20 ,

—CONHSO 2 R 21 , —CONHCOOR 22 or —SO 2 NHCOR 23 ;

R 2 and R 3 are independently H, halogen, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy or optionally substituted N(C 1 -C 6 alkyl) 2 ;

R 4 , R 5 and R 6 are independently H, halogen, CN, OH, optionally substituted C 1 -C 6 alkyl or optionally substituted C 1 -C 6 alkoxy;

R 7 and R 8 are independently H, optionally substituted C 1 -C 6 alkyl, optionally substituted aryl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted di-deutero-C 1 -C 10 -alkyl, optionally substituted C 2 -C 10 alkynyl, optionally substituted 5- to 7-membered monocyclic heteroaryl, optionally substituted 8- to 10-membered bicyclic heteroaryl, optionally substituted aryl C 1 -C 6 alkyl, arylsulfonyl, optionally substituted C 2 -C 6 alkenyl, or optionally substituted C 5 -C 8 cycloalkenyl,

provided that only one of R 7 and R 8 is H,

or R 7 and R 8 are taken together with the nitrogen to which they are attached to form an optionally substituted 4- to 10-membered monocyclic or bicyclic heterocyclic ring, or an optionally substituted 5- to 7-membered monocyclic heteroaryl ring;

R 9 is optionally substituted aryl; optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 1 -C 6 alkyl, optionally substituted 5- to 7-membered monocyclic heterocyclo, optionally substituted 7- to 10-membered bicyclic heterocyclo, optionally substituted 5- to 7-membered monocyclic heteroaryl, optionally substituted 8- to 10-membered bicyclic heteroaryl, optionally substituted C 1 -C 6 alkanoyloxy 5- to 7-membered monocyclic heteroaryl, R 24 CO—, optionally substituted C 1 -C 6 alkoxy, optionally substituted aryloxy, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, or optionally substituted C 5 -C 8 cycloalkenyl;

R 20 is optionally substituted C 1 -C 6 alkyl, CH 2 CF 3 , CF 3 or CF 2 CF 3 ;

R 21 is optionally substituted C 1 -C 6 alkyl or optionally substituted C 3 -C 8 cycloalkyl;

R 22 is optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 2 -C 6 alkenyl, or optionally substituted C 2 -C 6 alkynyl;

R 23 is optionally substituted C 1 -C 6 alkyl, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 2 -C 6 alkenyl, or optionally substituted C 2 -C 6 alkynyl;

R 24 is optionally substituted aryl-C 1 -C 6 -alkyl, optionally substituted C 1 -C 6 alkylaryl, aryl-C 1 -C 6 -alkyl(hydroxy), or optionally substituted C 1 -C 6 alkyl;

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

2. The compound as defined in claim 1 wherein:

W is CR 4 ;

V is CR 5 ;

Y is CR 6 ;

R 4 is H or halo;

R 5 is H or halo; and

R 6 is H or halo;

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

3. The compound as defined in claim 1 wherein

is phenyl or a 5- to 6-membered monocyclic heteroaryl.

4. The compound as defined in claim 3 wherein

is:

5. The compound as defined in claim 1 wherein:

R 1 is COOH, optionally substituted heterocyclyl, —NHSO 2 R 20 ,

—CONHSO 2 R 21 or —CONHCOOR 22 ;

R 2 is H, halogen, optionally substituted C 1 -C 6 alkyl or

optionally substituted C 1 -C 6 alkoxy; and

R 3 is H or C 1 -C 6 alkyl.

6. The compound as defined in claim 5 wherein:

R 1 is COOH, optionally substituted heterocyclyl, —NHSO 2 CH 3 ,

or —CONHSO 2 R 21 ;

where R 21 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl or CF 3 ;

R 2 is H, CH 3 , C 2 H 5 , CH 3 O, CF 3 O, F, or Cl; and

R 3 is H, CH 3 , or C 2 H 5 ;

and/or a stereoisomer, a tautomer or a pharmaceutically acceptable salt thereof.

7. The compound as defined in claim 1 wherein:

R 7 and R 8 are independently optionally substituted C 1 -C 6 alkyl, optionally substituted aryl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 3 -C 8 cycloalkyl, optionally substituted di-deutero-C 1 -C 6 -alkyl, optionally substituted C 1 -C 6 -alkylphenyl-C 1 -C 6 -alkyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted C 3 -C 8 -cycloalkyl-C 1 -C 6 -alkyl, optionally substituted C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl, optionally substituted 5- to 6-membered monocyclic heteroaryl, optionally substituted 7- to 10-membered bicyclic heteroaryl, optionally substituted aryl C 1 -C 6 alkyl, phenylsulfonyl, optionally substituted C 2 -C 6 alkenyl, or 5- to 6-membered monocyclic heteroaryl-C 1 -C 6 -alkyl,

or R 7 and R 8 are taken together with the nitrogen to which they are attached to form

(a) a 7- to 10-membered bicyclic heterocyclic ring which is optionally substituted with a phenyl-C 1 -C 6 -alkyl group, or

(b) a 5- to 7-membered monocyclic heterocyclic ring which is optionally substituted with 1 or 2 C 1 -C 6 alkyl groups, phenyl, a C 1 -C 6 -alkyl-substituted 5- to 7-membered monocyclic heteroaryl, and/or 1 or 2 halo groups; or

(c) a 5- to 7-membered monocyclic heteroaryl which is optionally substituted with a C 1 -C 6 alkyl;

R 9 is optionally substituted aryl; optionally substituted C 3 -C 8 cycloalkyl, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy, optionally substituted C 1 -C 6 alkylaryl, optionally substituted C 1 -C 6 alkoxyaryl, optionally substituted C 3 -C 8 cycloalkyl C 1 -C 6 alkyl, optionally substituted 5- to 7-membered monocyclic heterocyclo, optionally substituted 7- to 10-membered bicyclic heterocyclo, optionally substituted 5- to 6-membered monocyclic heteroaryl, optionally substituted 8- to 10-membered bicyclic heteroaryl, optionally substituted C 1 -C 6 alkanoyloxy 5- to 7-membered monocyclic heteroaryl, optionally substituted aryloxy, optionally substituted C 2 -C 6 alkenyl, optionally substituted C 2 -C 6 alkynyl, or optionally substituted C 5 -C 8 cycloalkenyl, C 2 -C 6 alkynylaryl, C 2 -C 6 alkynyloxyaryl, 5- to 6-membered heteroarylaryl, 5- or 6-membered heterocycloaryl, C 3 -C 8 cycloalkylaryl or C 1 -C 6 alkanoyl.

8. A compound of Formula (II)

wherein:

Y is CR 6 ;

is phenyl substituted with R 1 , and optionally substituted with R 2 and/or R 3

or

is a 5- to 7-membered monocyclic heteroaryl substituted with R 1 , and optionally substituted with R 2 and/or R 3 ;

R 1 is COOH, optional substituted tetrazol-5-yl, —NHSO 2 R 20

or —CONHSO 2 R 21 ;

R 20 is C 1 -C 6 alkyl or CF 3 ;

R 21 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl or CF 3 ;

R 2 is H, C 1 -C 6 alkyl, halo, optionally substituted C 1 -C 6 -alkoxy or N(C 1 -C 6 alkyl) 2 ,

R 3 is H, C 1 -C 6 alkyl, C 1 -C 6 alkoxy, or halo;

R 4 is H, halo or C 1 -C 6 alkyl;

R 5 is H, halo or C 1 -C 6 alkyl;

R 6 is H or halo;

R 7 and R 8 are independently H, optionally substituted C 1 -C 6 alkyl, optionally substituted aryl, optionally substituted C 3 -C 8 cycloalkyl, phenyl sulfonyl, dideutero-C 1 -C 6 -alkyl, optionally substituted C 3 -C 8 -cycloalkyl-C 1 -C 6 -alkyl, optionally substituted aryl-C 1 -C 6 -alkyl, optionally substituted C 2 -C 6 alkynyl, optionally substituted 5- to 7-membered monocyclic heterocyclo, optionally substituted 7- to 10-membered bicyclic heterocyclo, optionally substituted C 1 -C 6 -alkoxy-C 1 -C 6 -alkyl, 5- to 7-membered monocyclic heteroaryl-C 1 -C 6 -alkyl, C 2 -C 6 alkenyl, or C 5 -C 8 cycloalkenyl,

provided that only one of R 7 and R 8 is H,

and wherein the optional substituents on R 7 and R 8 , where possible, are 1 or 2 groups independently selected from hydroxy, optionally substituted C 1 -C 6 alkyl, optionally substituted C 1 -C 6 alkoxy, halo, optionally substituted aryl, optionally substituted C 3 -C 8 cycloalkyl, 5- to 7-membered monocyclic heteroaryl or 5- to 7-membered monocyclic heterocyclic;

or R 7 and R 8 are taken together with the nitrogen to which they are attached to form an optionally substituted 5- to 7-membered monocyclic heterocyclo ring, an optionally substituted 7- to 10-membered bicyclic heterocyclo ring, an optionally substituted 5- to 7-membered monocyclic heteroaryl ring, an optionally substituted 5- to 7-membered monocyclic heteroaryl-substituted 5- to 7-membered monocyclic heterocyclo ring, or a C 3 -C 8 -cycloalkyl-C 1 -C 6 -alkyl-substituted 7- to 10-membered bicyclic heterocyclo ring;

R 9 is H, C 1 -C 10 alkyl, aryl, optionally substituted phenyl, C 1 -C 6 alkylphenyl, optionally substituted C 1 -C 6 alkoxyphenyl, di-C 1 -C 6 -alkylphenyl, dihalo(C 1 -C 6 -alkyl)phenyl, C 2 -C 6 alkynylphenyl, optionally substituted 5- to 7-membered monocyclic heteroaryl, 7- to 10-membered bicyclic heteroaryl, C 3 -C 8 cycloalkyl, C 3 -C 8 -cycloalkyl-C 1 -C 6 -alkyl, C 2 -C 6 alkynyloxyphenyl, C 2 -C 6 -alkynyl-C 1 -C 6 -alkoxyphenyl, 5- to 7-membered monocyclic heteroarylphenyl, di-C 1 -C 6 -alkylaminophenyl, C 1 -C 6 alkyl sulfonylaminophenyl, 5- to 7-membered monocyclic heterocyclophenyl, C 3 -C 8 cycloalkyl optionally substituted phenyl, optionally substituted phenyl-C 1 -C 6 -alkylcarbonyl, phenyl-C 1 -C 6 -alkyl or C 1 -C 6 alkylcarbonyl;

and/or a pharmaceutically acceptable salt thereof, a tautomer thereof or stereoisomer thereof.

9. The compound according to claim 1 wherein the IC 50 in the HEK Human IDO-1 assay is <10 nM.

10. A pharmaceutical composition comprising one or more compounds according to claim 1 and a pharmaceutically acceptable carrier or diluent.

11. A method of inhibiting activity of indoleamine 2,3-dioxygenase comprising contacting said indoleamine 2,3-dioxygenase with a compound according to claim 1 or a pharmaceutically acceptable salt thereof.